SCHEMBL19586307

SCHEMBL19586307

COC(=O)C1CNc2cc(NC(=O)OC(C)(C)C)ccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA9 Q16790 1/20 0.42
EPHX2 P34913 1/20 0.41
BRD4 O60885 2/20 0.41
CREBBP Q92793 2/20 0.41
RXFP1 Q9HBX9 1/20 0.39
CYP17A1 P05093 3/20 0.39
SIRT2 Q8IXJ6 1/20 0.38
SIRT1 Q96EB6 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
NAMPT P43490 1/20 0.37
RORC P51449 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
HCRTR1 O43613 1/20 0.37
HCRTR2 O43614 1/20 0.37
BCL2 P10415 1/20 0.37
BECN1 Q14457 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22864635 0.74 SLC6A3 (0.38)
SCHEMBL22864660 0.74 MAPK1 (0.39) HDAC8
SCHEMBL7357650 0.74 EPHX2 (0.37) EPHX2ALDH1A1MEN1KMT2A
SCHEMBL18163647 0.72 RORC (0.41) CA12CA1CA9EPHX2SIRT2
SCHEMBL16856083 0.72 RORC (0.47) RORC
SCHEMBL17049233 0.71 RORC (0.52) RORC
SCHEMBL16843999 0.71 RORC (0.52) RORC
SCHEMBL16823741 0.71 RORC (0.53) RORC
SCHEMBL18143232 0.71 RORC (0.53) RORC
SCHEMBL16851276 0.71 RORC (0.53) RORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250057957-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2025-02-20 US disclosed
EP-4483875-A2 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 Therapeutics, Inc. (US) 2025-01-01 EP disclosed
EP-3454862-B1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS INC (US) 2024-09-11 EP disclosed
US-12048748-B2 Spirocyclic degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2024-07-30 US disclosed
US-20230095223-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2023-03-30 US disclosed
US-11185592-B2 Spirocyclic degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2021-11-30 US disclosed
US-11185592-B2 Spirocyclic degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2021-11-30 US disclosed
US-20210106688-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2021-04-15 US disclosed
US-20210106688-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2021-04-15 US disclosed
US-10660968-B2 Spirocyclic degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2020-05-26 US disclosed
US-10660968-B2 Spirocyclic degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2020-05-26 US disclosed
CN-109562113-A Spirocyclo-rongeur for target protein degradation C4医药公司 2019-04-02 CN disclosed
EP-3454862-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 Therapeutics, Inc. (US) 2019-03-20 EP disclosed
US-20190076540-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 Theraprutics, Inc. (US) 2019-03-14 US disclosed
WO-2017197036-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2017-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11185592-B2 Spirocyclic degronimers for target protein degradation STUB1, UBE3C, UBE3A CA12 4068/4885CA1 3972/4885CA9 4631/4885
US-20210106688-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION STUB1, UBE3C, UBE3A CA12 4068/4885CA1 3972/4885CA9 4631/4885
US-20250057957-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION STUB1, UBE3C, UBE3A CA12 4068/4885CA1 3972/4885CA9 4631/4885
US-10660968-B2 Spirocyclic degronimers for target protein degradation STUB1, UBE3C, UBE3A CA12 4068/4885CA1 3972/4885CA9 4631/4885
US-20230095223-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION STUB1, UBE3C, UBE3A CA12 4068/4885CA1 3972/4885CA9 4631/4885
US-20190076540-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION STUB1, UBE3C, UBE3A CA12 4068/4885CA1 3972/4885CA9 4631/4885
US-12048748-B2 Spirocyclic degronimers for target protein degradation STUB1, UBE3C, UBE3A CA12 4068/4885CA1 3972/4885CA9 4631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.